Investigating a new treatment for men with advanced prostate cancer resistant to standard therapies
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study is looking for men with advanced prostate cancer who haven't had success with common treatments to see if a new drug called SX-682, when combined with enzalutamide, can help improve their treatment results.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntrix Biosystems, INC. NIH-funded |
| Lab location | 1 site (Auburn, United States) |
| Project ID | NIH-10884438 on NIH RePORTER |
What this research studies
This research focuses on men with metastatic castration-resistant prostate cancer (mCRPC) who have not responded to standard treatments like abiraterone and enzalutamide. The study evaluates the combination of a new drug, SX-682, which inhibits specific chemokine receptors, alongside enzalutamide to see if it can improve treatment outcomes. By targeting the tumor microenvironment and overcoming resistance mechanisms, the research aims to provide a more effective therapy for these patients. Participants will receive the treatment and be monitored for their response over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have previously shown resistance to abiraterone.
Not a fit: Patients who have not been diagnosed with metastatic castration-resistant prostate cancer or those who have not previously received abiraterone may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves survival and quality of life for men with advanced prostate cancer.
How similar studies have performed: Other research has shown promise in targeting chemokine receptors in cancer treatment, indicating that this approach may be effective.
Where this research is happening
Auburn, United States
- Syntrix Biosystems, INC. — Auburn, United States (Active)
Researchers
- Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
- Study coordinator: Schuler, Aaron D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.